Research graph
References from PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21660 · 2021 · External reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger
10.1136/ijgc-2019-000308 · 2019 · External reference
Epithelial ovarian cancer
10.1016/s0140-6736(18)32552-2 · 2019 · External reference
How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
10.3389/fonc.2024.1335196 · 2024 · External reference
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
10.1038/nature05789 · 2005 · External reference
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
10.1038/nature03445 · 2005 · External reference
Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
10.1056/nejmoa1810858 · 2018 · External reference
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
10.1056/nejmoa1911361 · 2019 · External reference
Niraparib in patients with newly diagnosed advanced ovarian cancer
10.1200/jco.2020.38.15_suppl.6051 · 2019 · External reference
Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer
10.2217/fon-2021-0059 · 2021 · External reference
Incorporation of bevacizumab in the primary treatment of ovarian cancer
10.1056/nejmoa1104390 · 2011 · External reference
A phase 3 trial of bevacizumab in ovarian cancer
10.1056/nejmoa1103799 · 2011 · External reference
Unresolved reference
External reference
PARP inhibitor maintenance after first-line chemotherapy in advanced-stage epithelial ovarian cancer: A systematic review and meta-analysis
10.1001/jamanetworkopen.2025.41648 · 2025 · External reference
Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy
10.37766/inplasy2025.3.0096 · 2026 · External reference
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
10.7326/m14-2385 · 2015 · External reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · 2019 · External reference
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
10.3322/caac.70042 · 2026 · External reference
A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
10.1200/jco.22.01003 · 2022 · External reference
Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: A phase 3 randomized clinical trial
10.1001/jamaoncol.2023.2283 · 2023 · External reference
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
10.1038/s41591-024-03003-9 · 2024 · External reference
Exploring and comparing adverse events between PARP inhibitors
10.1016/s1470-2045(18)30786-1 · 2019 · External reference
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
10.1016/j.annonc.2020.08.2102 · 2020 · External reference
Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial
10.1097/ogx.0000000000001120 · 2023 · External reference
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
10.1016/j.annonc.2024.08.2241 · 2024 · External reference
PARP inhibitor maintenance after first-line chemotherapy in advanced-stage epithelial ovarian cancer: A systematic review and meta-analysis
10.1001/jamanetworkopen.2025.41648 · ExternalCitation · doi-reference
Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: A phase 3 randomized clinical trial
10.1001/jamaoncol.2023.2283 · ExternalCitation · doi-reference
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
10.1016/j.annonc.2020.08.2102 · ExternalCitation · doi-reference
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
10.1016/j.annonc.2024.08.2241 · ExternalCitation · doi-reference
Epithelial ovarian cancer
10.1016/s0140-6736(18)32552-2 · ExternalCitation · doi-reference
Exploring and comparing adverse events between PARP inhibitors
10.1016/s1470-2045(18)30786-1 · ExternalCitation · doi-reference
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
10.1038/nature03445 · ExternalCitation · doi-reference
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
10.1038/nature05789 · ExternalCitation · doi-reference
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
10.1038/s41591-024-03003-9 · ExternalCitation · doi-reference
A phase 3 trial of bevacizumab in ovarian cancer
10.1056/nejmoa1103799 · ExternalCitation · doi-reference
Incorporation of bevacizumab in the primary treatment of ovarian cancer
10.1056/nejmoa1104390 · ExternalCitation · doi-reference
Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
10.1056/nejmoa1810858 · ExternalCitation · doi-reference
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
10.1056/nejmoa1911361 · ExternalCitation · doi-reference
Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial
10.1097/ogx.0000000000001120 · ExternalCitation · doi-reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · ExternalCitation · doi-reference
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger
10.1136/ijgc-2019-000308 · ExternalCitation · doi-reference
Niraparib in patients with newly diagnosed advanced ovarian cancer
10.1200/jco.2020.38.15_suppl.6051 · ExternalCitation · doi-reference
A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
10.1200/jco.22.01003 · ExternalCitation · doi-reference
Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer
10.2217/fon-2021-0059 · ExternalCitation · doi-reference
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21660 · ExternalCitation · doi-reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · ExternalCitation · doi-reference
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
10.3322/caac.70042 · ExternalCitation · doi-reference
How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
10.3389/fonc.2024.1335196 · ExternalCitation · doi-reference
Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy
10.37766/inplasy2025.3.0096 · ExternalCitation · doi-reference
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
10.7326/m14-2385 · ExternalCitation · doi-reference
